Cybin (OTCMKTS:CYBN) Trading Down 2%

Cybin Inc. (OTCMKTS:CYBN) fell 2% during mid-day trading on Thursday . The company traded as low as $0.36 and last traded at $0.37. 1,714,145 shares traded hands during mid-day trading, a decline of 67% from the average session volume of 5,246,800 shares. The stock had previously closed at $0.38.

Cybin Price Performance

The company has a market capitalization of $151.07 million, a price-to-earnings ratio of -1.74 and a beta of 0.43. The business has a 50-day moving average price of $0.39 and a 200-day moving average price of $0.43.

Cybin (OTCMKTS:CYBN) last posted its quarterly earnings data on Wednesday, February 14th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.04). As a group, sell-side analysts predict that Cybin Inc. will post -0.19 EPS for the current year.

Hedge Funds Weigh In On Cybin

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC lifted its holdings in shares of Cybin by 370.6% in the first quarter. Jane Street Group LLC now owns 74,631 shares of the company’s stock valued at $61,000 after purchasing an additional 58,771 shares in the last quarter. Virtu Financial LLC boosted its stake in Cybin by 104.0% in the fourth quarter. Virtu Financial LLC now owns 90,467 shares of the company’s stock valued at $27,000 after acquiring an additional 46,129 shares during the last quarter. Royal Bank of Canada grew its stake in shares of Cybin by 926.4% during the third quarter. Royal Bank of Canada now owns 109,239 shares of the company’s stock worth $52,000 after purchasing an additional 98,596 shares during the period. Belpointe Asset Management LLC grew its position in shares of Cybin by 21.5% during the 1st quarter. Belpointe Asset Management LLC now owns 313,705 shares of the company’s stock worth $121,000 after buying an additional 55,600 shares during the period. Finally, Penserra Capital Management LLC raised its position in shares of Cybin by 55.8% in the 1st quarter. Penserra Capital Management LLC now owns 407,309 shares of the company’s stock valued at $223,000 after acquiring an additional 145,929 shares during the period. Institutional investors and hedge funds own 17.94% of the company’s stock.

About Cybin

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.